Gefitinib Inhibits Invasive Phenotype and Epithelial-Mesenchymal Transition in Drug-Resistant NSCLC Cells with MET Amplification
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Gefitinib Inhibits Invasive Phenotype and Epithelial-Mesenchymal Transition in Drug-Resistant NSCLC Cells with MET Amplification
Authors
Keywords
-
Journal
PLoS One
Volume 8, Issue 10, Pages e78656
Publisher
Public Library of Science (PLoS)
Online
2013-10-23
DOI
10.1371/journal.pone.0078656
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Molecular Mechanisms Underlying the Antitumor Activity of 3-Aminopropanamide Irreversible Inhibitors of the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer
- (2015) Elena Galvani et al. NEOPLASIA
- Baicalin Suppresses Migration, Invasion and Metastasis of Breast Cancer via p38MAPK Signaling Pathway
- (2013) Xiu- Wang et al. Anti-Cancer Agents in Medicinal Chemistry
- Does T790M Disappear? Successful Gefitinib Rechallenge After T790M Disappearance in a Patient With EGFR-Mutant Non–Small-Cell Lung Cancer
- (2013) Akito Hata et al. Journal of Thoracic Oncology
- EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: A case–control study of overall survival
- (2013) M. Faehling et al. LUNG CANCER
- S100A8 and S100A9 promotes invasion and migration through p38 mitogen-activated protein kinase-dependent NF-κB activation in gastric cancer cells
- (2013) Chae Hwa Kwon et al. MOLECULES AND CELLS
- Cancer statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Current Status and Future Perspectives in the Development of Novel Irreversible Inhibitors for the Treatment of Mutant Non-small Cell Lung Cancer
- (2012) Elena Galvani et al. CURRENT PHARMACEUTICAL DESIGN
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Beyond Progressive Disease: A Retrospective Analysis for Japanese Patients with Activating EGFR Mutations
- (2012) Kenichi Nishie et al. Journal of Thoracic Oncology
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Continued treatment with gefitinib beyond progressive disease benefits patients with activating EGFR mutations
- (2012) Kazuhiro Asami et al. LUNG CANCER
- Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors
- (2012) Mizuki Nishino et al. LUNG CANCER
- Epithelial Mesenchymal Transition in Drug Resistance and Metastasis of Lung Cancer
- (2012) Fariz Nurwidya et al. Cancer Research and Treatment
- STAT6 expression in glioblastoma promotes invasive growth
- (2011) Barbara C Merk et al. BMC CANCER
- Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis
- (2011) Satoshi Watanabe et al. BMC CANCER
- Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design
- (2011) J. E. Chaft et al. CLINICAL CANCER RESEARCH
- Epithelial to Mesenchymal Transition in an Epidermal Growth Factor Receptor-Mutant Lung Cancer Cell Line with Acquired Resistance to Erlotinib
- (2011) Kenichi Suda et al. Journal of Thoracic Oncology
- Up-Regulation of Sonic Hedgehog Contributes to TGF-β1-Induced Epithelial to Mesenchymal Transition in NSCLC Cells
- (2011) Ma'in Y. Maitah et al. PLoS One
- Optimization of Dosing for EGFR-Mutant Non-Small Cell Lung Cancer with Evolutionary Cancer Modeling
- (2011) J. Chmielecki et al. Science Translational Medicine
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- (2011) L. V. Sequist et al. Science Translational Medicine
- Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo
- (2010) Lei Gu et al. ENDOCRINE-RELATED CANCER
- Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines
- (2009) Silvia La Monica et al. BIOCHEMICAL PHARMACOLOGY
- Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification
- (2009) Takeshi Yoshida et al. CANCER SCIENCE
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy
- (2008) Stuart Thomson et al. CLINICAL & EXPERIMENTAL METASTASIS
- Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines
- (2008) A. Cavazzoni et al. MOLECULAR CANCER THERAPEUTICS
- Signaling networks assembled by oncogenic EGFR and c-Met
- (2008) A. Guo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started